Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 5/20 | 0.45 |
| ▸ | PTK6 | Q13882 | 4/20 | 0.45 |
| ▸ | ABL1 | P00519 | 4/20 | 0.45 |
| ▸ | HCK | P08631 | 3/20 | 0.45 |
| ▸ | BLK | P51451 | 3/20 | 0.45 |
| ▸ | FRK | P42685 | 2/20 | 0.45 |
| ▸ | LCK | P06239 | 2/20 | 0.41 |
| ▸ | FYN | P06241 | 2/20 | 0.41 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.41 |
| ▸ | CDK1 | P06493 | 2/20 | 0.41 |
| ▸ | ROS1 | P08922 | 2/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.41 |
| ▸ | CLK2 | P49760 | 2/20 | 0.41 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.41 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17699271 | 0.93 | SRC (0.44) | SRCPTK6ABL1HCKBLK | |
| SCHEMBL16701529 | 0.83 | PTK6 (0.45) | SRCPTK6ABL1HCKBLK | |
| SCHEMBL17267635 | 0.81 | DYRK3 (0.47) | SRCBLKLCKFYNDYRK3 | |
| SCHEMBL17853709 | 0.81 | SRC (0.42) | SRCPTK6ABL1HCKBLK | |
| SCHEMBL19294566 | 0.81 | PTK6 (0.43) | SRCPTK6ABL1HCKBLK | |
| SCHEMBL29669814 | 0.81 | PTK6 (0.43) | SRCPTK6ABL1HCKBLK | |
| SCHEMBL17915672 | 0.81 | SRC (0.42) | SRCPTK6ABL1HCKBLK | |
| SCHEMBL23157415 | 0.80 | SRC (0.41) | SRCPTK6ABL1HCKBLK | |
| SCHEMBL24651184 | 0.79 | DYRK3 (0.48) | SRCPTK6ABL1HCKBLK | |
| SCHEMBL19294569 | 0.79 | HDAC1 (0.50) | SRCBLKLCKFYNDYRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580432-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2017-02-28 | — | — | US | disclosed |
| US-20160115168-A1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115168-A1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | BTK, JAK2, SYK | SRC 18/4885PTK6 63/4885ABL1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.